🇺🇸 FDA
Patent

US 10420793

Composition of novel carbohydrate drug for treatment of human diseases

granted A61KA61K31/70A61K31/715

Quick answer

US patent 10420793 (Composition of novel carbohydrate drug for treatment of human diseases) held by GALECTIN THERAPEUTICS, INC. expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GALECTIN THERAPEUTICS, INC.
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/70, A61K31/715, A61K31/738, A61K45/06